Loading
Womb precancer in women with obesity is usually treated with a hormone coil or hysterectomy. Weight-loss drugs might reverse it and protect fertility.
Womb precancer in women with obesity is usually treated with a hormone coil or hysterectomy, so this idea tests whether adding a GLP-1 receptor agonist to the levonorgestrel intrauterine system reverses atypical endometrial hyperplasia and protects fertility. Obesity drives the condition and a substantial share of cases progress to cancer; weight loss after bariatric surgery reverses hyperplasia, and GLP-1 drugs offer a non-surgical route. The aim is more complete regression and less relapse than the intrauterine system alone. The test is a 300-woman RCT with histological regression at six months as the endpoint. At early-clinical maturity it addresses the bottleneck Prevention we already have is not deployed and links to chemoprevention and endometrial cancer.
Shares GLP-1 receptor agonists and obesity-related cancer risk, Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States, Chemoprevention & risk-reducing surgery, Diet, exercise and lifestyle roadmap: causes established → interventions that disappointed → exercise proven as treatment.
Shares Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States, Diet, exercise and lifestyle roadmap: causes established → interventions that disappointed → exercise proven as treatment, Prevention we already have is not deployed.
Shares Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States, Chemoprevention & risk-reducing surgery, Prevention we already have is not deployed.
Shares Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States, Prevention we already have is not deployed.
Shares Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States, Prevention we already have is not deployed.
Shares Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States, Prevention we already have is not deployed.
Shares Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States, Prevention we already have is not deployed.
Shares Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States, Prevention we already have is not deployed.